Showing results (121-130 of 148) with videos related to
Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trialS M Blaney, N L Seibel, M O'Brien, et al.Antimicrobial Agents and Chemotherapy|March 1, 1988
Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndromeP Rogers, C J Allegra, R F Murphy, et al.Antimicrobial Agents and Chemotherapy|July 14, 1998
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosingB U Mueller, B D Anderson, M Q Farley, et al.Antimicrobial Agents and Chemotherapy|April 2, 1999
Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbitsD P Callender, N Jayaprakash, A Bell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factorD M Savarese, A M Denicoff, S L Berg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigmW H Wilson, L Sorbara, W D Figg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1991
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinomaJ L Grem, N McAtee, R F Murphy, et al.Cancer Research|August 1, 1990
Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day scheduleP C Adamson, F M Balis, J Miser, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1987
The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeysJ A Kelley, C L Litterst, J S Roth, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapyW H Wilson, C Jamis-Dow, G Bryant, et al.Pageof 15